Proteomics International (ASX:PIQ) - Managing Director, Dr Richard Lipscombe
Managing Director, Dr Richard Lipscombe
Source: Proteomics International
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Proteomics International Laboratories (PIQ) has filed a pre-submission package to the United States Food and Drug Administration (FDA)
  • The company is seeking additional regulatory approval for the kit version of its PromarkerD diabetic kidney disease test
  • Proteomics expects to meet with the FDA to progress clearance within 10 weeks
  • With FDA clearance and CE Mark approval, the company will have access to over half of the global IVD diagnostic market
  • Proteomics International Laboratories is up 4.58 per cent and trading at 80 cents per share

Proteomics International Laboratories (PIQ) has filed a pre-submission package to the United States Food and Drug Administration (FDA).

The company is seeking additional regulatory approval for the kit version of its PromarkerD diabetic kidney disease test. 

Promarker D uses a unique protein fingerprint to predict the onset of diabetic kidney disease up to four years before clinical symptoms start to develop. If doctors can accurately diagnose people who are at risk of developing Type 2 diabetes, they can provide treatment plans that could delay or even stop the disease entirely.

As part of the pre-submission process, Proteomics will meet with the FDA to consult on the best regulatory path for PromarkerD. During this time, the company will present the FDA with peer-reviewed clinical performance data, which demonstrates the effectiveness of the test.

Proteomics expects to meet with the FDA to progress its clearance within 10 weeks. 

If PromarkerD gains FDA approval, the company will be able to deploy its easy-to-use, inexpensive blood test throughout the United States.

The PromarkerD test already has CE Mark approval in the European Union and would benefit greatly from approval by the FDA.

The company’s Managing Director, Dr Richard Lipscombe, stated that FDA approval would be a significant commercialisation milestone for PromarkerD.

“FDA sign-off would assure potential licensing partners and consumers that the test has been developed and manufactured to US safety, health, and environmental protection standards,” he said.

“We CE Mark approval and FDA clearance, we would have access to more than 70 per cent of the global IVD diagnostic market,” he added.

Dr Lipscombe also noted that the company’s progression towards FDA approval for PromarkerD has conveniently coincided with increasing demand from U.S. diagnostic companies to broaden their testing capabilities.

Proteomics International Laboratories is up 4.58 per cent, trading at 80 cents per share at 1:24 pm AEDT.

piq by the numbers
More From The Market Online

Emvision Medical Devices unlocks traumatic brain injury First Responder with $3m grant

EMVision Medical Devices has been awarded a $3 million grant the Australian government’s national CRC-P program.

Immutep obtains encouraging disease-free survival in phase II sarcoma trial

Immutep has unveiled new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery.

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…